FORT WORTH, Texas, Aug. 11 /PRNewswire-FirstCall/ -- Wound Management Technologies, Inc., (OTC Bulletin Board: WNDM) a rapidly growing provider of specialty medical products, announced today that its subsidiary Wound Care Innovations, LLC, has reached agreement in principle with Biocure S.r.l. of Milan, Italy for the exclusive distribution in Italy of Wound Care's patented collagen CellerateRx(R) products. The final contract is expected to be finalized by the end of September.
As part of the agreement, Biocure will assist Wound Care with obtaining a CE Mark for Cellerate.
Cathy Bradshaw, president of Wound Care Innovations, said, "This is an important first step in providing Cellerate to Europe and the broader global markets. Diabetes is a growing worldwide health problem. We are strongly focused in building a national and global distribution network so that those suffering from the effects of diabetes worldwide can have access to the important wound management capabilities of Cellerate. Clinicians are having amazing results with Cellerate, particularly with diabetic wounds, and studies continue to support this. We are looking forward to obtaining a CE Mark for Cellerate, which will facilitate the expansion of sales in Europe and elsewhere.
"Global projections for the diabetes epidemic show an increase from 189 million patients in 2003 to 324 million patients in 2025, an increase of 72%. This is significant as statistics show that every 30 seconds a lower limb is lost somewhere in the world as a consequence of diabetes. In fact, diabetic ulcers are estimated to occur in 15% of all patients with diabetes. The direct cost of an amputation is estimated to be between $30,000 - $60,000," Bradshaw said.
Giovanni Pinamonti, President of Biocure said, "We are pleased with the opportunity to be appointed as the exclusive distribution channel for Cellerate in Italy, where there is a large and growing market for the kind of wound care provided by Cellerate. These products have demonstrated excellent results in evidence-based studies for those suffering from diabetes. We expect Cellerate will be an important addition in our ability to provide valuable healthcare products to the Italian market."
Biocure S.r.l. has been known for years in the pharmaceutical market of OTC products. Recently, they have included Corporate managers with long standing success stories with prestigious multinational pharmaceutical companies. This has allowed the acquisition of strategic implementation of partnerships with international research groups, engaged in developing proprietary and innovative technologies. Biocure is based in Milan, Italy. For more information, please visit the website http://www.biocure.it
About Wound Management Technologies, Inc.:
Wound Management Technologies, Inc. (OTCBB:WNDM), with its corporate headquarters in Fort Worth, Texas, markets and distributes wound care products to the healthcare market under patented technology licensed to the company. The company is positioned and seeks to be a leading provider of wound care products. For more information on the company please visit the company's website at www.celleraterx.com.
For product information contact Cathy Bradshaw at 954-315-9242. For shareholder relations, contact Lucy Singleton at 817-820-7080.
Safe Harbor Statement Under The Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development are "forward-looking statements," within the meaning of the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks and uncertainties detailed in the Company's SEC filings. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.
|SOURCE Wound Management Technologies, Inc.|
Copyright©2009 PR Newswire.
All rights reserved